tiprankstipranks
Trending News
More News >
Pure Biologics SA (DE:PQB)
FRANKFURT:PQB
Germany Market
Advertisement

Pure Biologics SA (PQB) Drug Pipeline

Compare
0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Pba-0111
Triple Negative Breast Cancer, Head And Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
Early Phase I
Recruiting
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
Nov 19, 2024
Pba-0405
Triple Negative Breast Cancer, Head And Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
Early Phase I
Completed
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
Feb 15, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Pure Biologics SA (PQB) have in its pipeline
      PQB is currently developing the following drugs: Pba-0111, Pba-0405. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis